Crohn’s & Colitis Congress (CCC 2024)
Bellagio, Las Vegas 25 January 2024 - 28 February 2024
Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).
Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
22 Feb 2024
Does multiple biosimilar switching induce flare in IBD patients?
Multiple biosimilar infliximab (IFX) switching among patients with inflammatory bowel disease (IBD) does not seem to give rise to disease flares at 12 months compared to those who continued using IFX originator or those on single IFX biosimilar switch, a study has shown.
Does multiple biosimilar switching induce flare in IBD patients?
17 Feb 2024
IBD patients see improvements after surgical intervention
A surgical intervention performed for inflammatory bowel disease (IBD) appears to confer favourable effects on patient-reported outcomes such as pain and overall health, according to a prospective, longitudinal cohort study.
